A stronger Wegovy dose is now approved — here's the full picture

The misconception worth correcting first: a higher dose does not mean a faster start

A lot of the coverage around the 7.2mg approval has left people with the impression that they can simply ask for the stronger pen and begin there. That's not how it works, and a prescriber would not do it safely. The 0.25mg starting dose exists specifically to give your digestive system time to adjust, skipping ahead causes the kind of nausea and vomiting that makes people abandon treatment altogether. The approved titration moves roughly every four weeks, guided by tolerance and response. The 7.2mg pen is a destination for patients who have moved through the earlier doses and still have clinical reason to escalate. If you're wondering whether the 0.5mg dose is actually stronger than the 0.25mg starting dose, that question gets a thorough answer in our dedicated guide. If you're curious about how meaningful the gap is between doses, the Wegovy dose guide walks through the full schedule.

The other common misreading is that 7.2mg replaces 2.4mg as the new standard maintenance dose. It doesn't. For many people, 2.4mg delivers good results with a manageable side-effect profile. The higher dose is an option the prescriber reaches for when it's clinically warranted.

What the trial evidence says about the stronger dose

The weight-loss figures at 7.2mg are genuinely significant. Across a 72-week period, participants on the higher dose achieved an average reduction of around 20.7% of body weight, a result that narrows the gap with tirzepatide 15mg, which produced roughly 20–21% average loss in the SURMOUNT-1 trial, as NICE's appraisal of tirzepatide (TA1026) discusses. For context, the 2.4mg Wegovy dose (which was the standard maintenance dose before the January 2026 authorisation) produced around 15% average weight reduction in the STEP 1 trial. So the additional dose matters for certain patients. Whether you'd be one of them is genuinely a clinical judgement. If you want to understand how strong the 0.5mg dose really is in practical terms, that page puts the early titration steps into perspective. If you want to understand where 2.4mg sits before the step up, there's a detailed look at the 2.4mg dose that helps put the numbers in context.

It's natural to feel a mix of hope and impatience when a more effective option is announced. Many people following this treatment have been on long NHS waiting lists or struggled to find reliable private access, hearing that a stronger version exists can feel like the answer. That's understandable. The evidence is encouraging. The key is that 7.2mg works within a supervised programme, not as a shortcut to it.

The new pen format and what it changes practically

The dedicated 7.2mg pen approved in April 2026 is a single pre-set weekly injection with an auto-dosing mechanism, a built-in covered needle, and a lock after use. Before that pen existed, the January 2026 authorisation required the equivalent of three separate 2.4mg pens per week, a significant practical burden. The dedicated single-dose format simplifies administration considerably. Storage requirements are the same as for other Wegovy pens: refrigerated at 2–8°C, with a limited room-temperature window detailed in the Patient Information Leaflet. The MHRA's full approval details are covered in the breakdown of the 7.2mg MHRA approval. For anyone thinking about how cost sits alongside these developments, the weight-loss treatment overview gives useful context on what private treatment involves.

Who is eligible for the 7.2mg dose, and how prescribing works

The MHRA's licence for the 7.2mg dose applies to adults with a BMI of 30 or above. It is not authorised for adults with a BMI below 30, and it does not extend to the cardiovascular indication that Wegovy also holds in the UK. That eligibility boundary matters: a prescriber cannot lawfully prescribe it outside those parameters. If you're already established on the 2.4mg dose through a regulated service and your BMI and clinical picture support escalation, your prescriber can discuss whether moving to 7.2mg is appropriate at your next review. If you're new to treatment and wondering what the highest available dose looks like across the full landscape, the strongest Wegovy dose page covers that in full. Prescription-only medicines like Wegovy require a clinical assessment every time; at nume, every repeat is reviewed by a GPhC-registered Independent Prescriber before anything is dispensed. If you'd like to discuss your options with our clinical team, you can read more about our approach on the prescribers page or start your free consultation when you're ready.